Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
How a "Non Traditional" background can lead to success as an MSL
Summary
In this episode, Robert Rosti shares his unique journey from medical information to becoming a Medical Science Liaison (MSL). He provides insights into the transition process, emphasizing the importance of networking and professional etiquette. Robert discusses how to leverage diverse backgrounds and offers tips for breaking into the MSL industry without prior experience. He highlights the significance of preparation, emotional intelligence, and mastering LinkedIn for effective networking. The conversation covers navigating the cultural shift from academia to industry and strategies for standing out with a nontraditional background. Robert also delves into interview techniques and the dedication required for a successful MSL career.
My guest today is Robert Rosti, Sr Medical Science Liaison at Biogen. He discusses how his "Non-Traditional" background led to great success as a Medical Science Liaison.
In this episode we discuss:
- Rob’s background
- His education and where his career began
- What made him want to transition to the industry and how did he go about it?
- How Rob landed in medical affairs and why he wanted to be an MSL?
- His advice for others who may have a non-traditional background
- What he feels is most important for ANYONE trying to transition into the industry and become an MSL?
- His advice to those that are looking to build a career in Medical Affairs
Medical Science Liaison, MSL career tips, networking in medical affairs, transitioning to industry, non-traditional background success
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO